LMD-584 is an agonist of CCR8. LMD-584 is also an analog of LMD-009.

Izicopan (INF056) is a complement factor C5a receptor antagonist. Izicopan inhibits C5a-induced calcium mobilization with an IC50 of 10-100 nM.

1192U90 is an antipsychotic agent, dopamine D2 receptor antagonist as well as serotonin 5-HT1a receptor agonist. 1192U90 reduces the number of spontaneously firing neurons in the limbic dopamine system.

AG-1284 is a HIV proteinase inhibitor with an EC50 of 0.5 mg/mL. AG-1284 can be used for the research of infection.

ERK5 ligand-1 is a is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). ERK5 ligand-1 can be used to design PROTAC, such as PROTAC ERK5 degrader-1.

HM12 is a covalent inhibitor of L-/T-type calcium channels. HM12 can strongly inhibit the Cav1.2 (L-type) and Cav3.2 (T-type) calcium channels, and has selectivity for the N-type channels. HM12 produces an irreversible inhibition that persisted after washout. HM12 can be used to study diseases such as hypertension, pain, epilepsy, etc.

F-0401 is a calcium antagonist with platelet-activating factor receptor (PAFR) antagonistic action. F-0401 can be used for the research of neurological disease, such as stroke.

TY-51924 (ethanol sodium) is a highly selective NHE-1 inhibitor (IC50 = 0.095 μM). TY-51924 (ethanol sodium) can significantly reduce the infarct size and myocardial enzyme release. TY-51924 (ethanol sodium) is commonly used in the study of ischemia-reperfusion injury.

LXE408 fumarate is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 fumarate has an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. LXE408 fumarate has a low propensity to cross the blood brain barrier. LXE408 fumarate has the potential for visceral leishmaniasis (VL) research.

BMS-626531 is a potent and selective p38α MAP kinase inhibitor. BMS-626531 can be used for the research of cancer.

VNRX-9945 is a potent, broadly and orally active HBV CAM (capsid assembly modulator) with an EC50 of 2.6 nM. VNRX-9945 exhibits excellent and broad antiviral activity against multiple HBV genotypes in vitro, along with favorable pharmacokinetic profiles across multiple species. VNRX-9945 demonstrates robust antiviral efficacy in the adeno-associated virus mice models of HBV (AAV-HBV) infection.

Bacillibactin (Corynebactin) is a cyclic tricatecholate siderophore. Bacillibactin’s primary function is to facilitate bacterial iron acquisition by chelating iron ions (Fe3+) from the environment, thereby aiding bacterial survival under iron-limited conditions. Bacillibactin exhibits direct antimicrobial activity, such as inhibition of the growth of the producing bacteria Pseudomonas aeruginosa and Aeromonas veronae, as well as plant pathogens such as Pseudomonas syringae.Bacillibactin can be used in antibacterial and antifungal research.

DuP-532 is an angiotensin type 1 receptor antagonist with potential activity in the suppression of hypertension and heart failure. DuP-532 can react with a range of aryl and heteroaryl halides to form perfluoroalkyl(hetero)arenes in moderate to high yields. Computational studies of DuP-532 suggest that coordination of a second phenyl ring ligand may lower the energy barrier for decarboxylation of perfluorocarboxylates, thereby promoting the perfluoroalkylation reaction.

MGB1Y is a noncovalent DNA minor groove binder (MGB). MGB1Y potently inhibits cancer cells proliferation and topoisomerase I activity. MGB1Y downregulates their breast cancer-related genes in MCF7 and MDA-MB-231 cells. MGB1Y has a broad-spectrum anticancer activity, such as breast cancer, colon cancer, and leukemia.

MGB4 is a DNA minor groove binder. MGB4 binds to ARE-containing DNA and inhibition of topoisomerase I activity. MGB4 can impacts key cellular pathways, including inhibition oftranslation and alterations in sphingolipid and amino acid metabolism. MGB4 also reduces spermine and spermidine metabolism companied with Doxorubicin). MGB4 can be used for the research of cancer, such as Prostate cancer.

LY 255262 is an antibacterial agent. LY 255262 exhibits potent inhibitory effects against a variety of Gram-positive and Gram-negative bacteria in vitro. LY 255262 has MIC values of 64, 0.25, 0.5, 0.25, 0.25, 1, and 1 μg/mL for Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza, Escherichia coli, Klebsiella, Enterobacter aerogenes, and Serratia, respectively. LY 255262 has a relatively weak inhibitory effect on Pseudomonas (MIC >128 μg/mL). LY 255262 can be used in antibacterial research.

SC-77964 is a potent, selective and orally active matrix metalloprotease (MMP) inhibitor. SC-77964 shows IC50 values < 0.1 nM against MMP-2, MMP-9, and MMP-13. SC-77964 can be used for the research of cancer and inflammation, such as melanoma.

Carpipramine is an antipsychotic agent that belongs to the iminodibenzyl class. Carpipramine is a potent dopamine antagonist which blocks alpha 1- and alpha 2-adrenoceptors. Carpipramine also has antagonist properties with respect to serotonin (5-ΗΤ2) receptors. Carpipramine exhibits antipsychotic and anti-depressant effects. Carpipramine can be used for the research of neurological disease, such as post-traumatic stress disorder (PTSD) and depression.

SGC-NSP2hel-1 (RA-0188293), a chemical probe, is a potent, specific and orally active nsP2 inhibitor. SGC-NSP2hel-1 has broad spectrum activity against multiple alphaviruses of the nsP2 helicase with a CC50 > 250 μM. SGC-NSP2hel-1 (RA-0188293) shows selectivity index > 4000 against human RNA helicases. SGC-NSP2hel-1 reduces virus replication and limited virus-induced pathology by forming a stable complex with nsP2 and ATP in a preclinical small animal model of CHIKV disease.

Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma.

3-Fluoro-desmethyl-cabozantinib is an BCL6 ligand that can be used in the synthesis of PROTACs, such as SJF-8240.

(R,R)-VRT-534 is the (R,R)-enantiomer of VRT-534). VRT-534 (Compound 3) is a chemical chaperone targeting connexin 26 (Cx26). Vrt-534 exhibits dose-responsive binding to recombinant WT Cx26 and mutant Cx26 K188N with EC50s of 19 and 5 μM, respectively. Vrt-534 can be used in research related to hearing impairment.

1,4-Naphthoquinone-NH-C2-NH-Trolox is a brain-penetrant Trolox-vitamin K conjugate with neuroprotective activity. 1,4-Naphthoquinone-NH-C2-NH-Trolox can inhibit oxytosis, ferroptosis, ATP depletion and ROS production. 1,4-Naphthoquinone-NH-C2-NH-Trolox selective suppresses M1 markers expression. 1,4-Naphthoquinone-NH-C2-NH-Trolox can be used for the research of neurological disease, such as Alzheimer’s disease (AD).

cBu-Cit-PAB (Compound 13) is a key intermediate of ADC linker. cBu-Cit-PAB can be used for synthesis of antibody-drug conjugates (ADCs).

UTPU (trisodium) (Compound 19) is a selective P2Y6R agonist with an EC50 of 0.4 μM. UTPU (trisodium) can activate the intracellular calcium signaling pathway mediated by P2Y6. UTPU (trisodium) can be used for the research of inflammation.

Ara-UTP is a sugar-modified nucleotide triphosphate that deceives RNA polymerases and blocks chain extension.

APL-1082 (exo-EVC-Exatecan) is a drug-Linker conjugate that can be used for ADC synthesis. Its structure contains Exatecan (ADC payload) and linker.

LM-D01 is a Drug-Linker Conjugates for ADC. LM-D01 consists of the ADC Cytotoxin Exatecan-3-amine178265) and a linker MC-GGFG-NH-CH2-O-propionic acid. LM-D01 can be used for synthesis of ADCs.

JSSW-001 is a drug-linker compound applicable for the preparation of antibody-drug conjugates (ADCs). JSSW-001 can be used for the study of cancer.

Tub114 is a drug-linker conjugate for ADC. Tub114 is a Tubulysin B analog with a stable hydrophilic linker. Tub114 can be used for synthesis of ADCs.